Crysalin
Crysalin has been formed to commercialise novel nanostructured materials that that can be applied to a number of problems in various industries. Initially, it will focus on developing products that improve the efficiency of the preclinical phase of drug development, which currently accounts for approximately 66% total budget and 58% of total development time before a drug is introduced to the market. Based on its proprietary technology platform, Crysalin has the potential to make structure-based drug discovery routinely used, thereby cutting the time to develop small molecule drugs by approximately 3 years and reducing the cost of development by 30%. It will do so by making it technically easy, inexpensive and quick to determine protein structure, which is the key to rational drug design.
Due to the potential impact of the protein structure reagents technology platform, Crysalin could create a new market for relatively low-cost protein structure determination that could generate significant value in reagent sales alone within 10 years.
The company will make money by providing services for structure based drug discovery, selling high value research reagents and licensing its technologies for use in other applications in markets outside its core focus.
The technology platform is based on 8 man-years of research by Professor Martin Noble and Dr John Sinclair from the Department of Biochemistry at University of Oxford. A worldwide patent protects the core technology.